Benefits
Leg vein comfort from the rutin derivative hydroxyethylrutosides
A review of 15 randomized trials (1,643 participants) found that, in pooled comparisons with placebo, hydroxyethylrutosides, a semi-synthetic rutin derivative, eased leg pain, heaviness and cramps in adults with chronic venous insufficiency. The gains were modest, the trials were of limited quality, and the results do not transfer to plain dietary rutin.
Capillary strength support
Rutin is used in many countries as a vasoprotectant, an ingredient meant to support blood-vessel walls, and is found in many multivitamin and herbal products. No recent placebo-controlled trial of plain rutin has measured capillary strength, bruising or bleeding in people, so this use rests on custom and on research with rutin derivatives.
Antioxidant activity
Rutin binds iron and acts as an antioxidant in laboratory and animal studies. In a placebo-controlled trial in 50 adults with type 2 diabetes, 500 mg/day for 3 months raised total antioxidant capacity and lowered the oxidative stress marker malondialdehyde compared with placebo, but a 6-week trial in 18 healthy women found no change in plasma antioxidant status.
Inflammatory marker support
In a 3-month placebo-controlled trial in 50 adults with type 2 diabetes, 500 mg/day of rutin lowered the inflammatory marker interleukin 6 (IL-6) compared with placebo. This is one small trial measuring a blood marker; no trial has measured a clinical inflammatory outcome with plain rutin.
Blood sugar and cholesterol markers
In 50 adults with type 2 diabetes, 500 mg/day of rutin for 3 months lowered fasting glucose, HbA1c, insulin resistance, LDL and total cholesterol and raised HDL compared with placebo. A 12-week trial in 87 adults with overweight found that the same dose did not change insulin-producing cell response to a glucose drink.
Mechanism of action
Quercetin prodrug
In a crossover study in 16 healthy volunteers, no rutin was detected in plasma after oral rutin, only quercetin and its glucuronide and sulfate forms. Quercetin peaked later than after plain quercetin (about 6.5 to 7.5 versus 1.9 to 4.8 hours) with similar overall exposure, but absorption from rutin varied far more between people.
Vasoprotectant activity
Rutin and quercetin are used in many countries as vasoprotectants. The human data on leg swelling come from related compounds: in pooled placebo-controlled trials of oral vein-support compounds (phlebotonics), half of them testing rutosides, lower-leg swelling was slightly reduced. How plain rutin acts on capillaries in people has not been established in modern controlled studies.
Antioxidant and iron binding
Rutin shows antioxidant and iron-chelating activity in laboratory and animal studies; in a genetic mouse model of iron overload, oral rutin for 21 days lowered liver ferritin and serum transferrin saturation. In people, one 3-month trial found higher total antioxidant capacity and lower malondialdehyde than placebo, while a 6-week trial found no change in plasma antioxidant status.
Clotting enzyme (PDI) inhibition
In a laboratory screen rutin (quercetin-3-rutinoside) selectively inhibited protein disulfide isomerase (PDI), an enzyme involved in clot formation. It reduced human and mouse platelet aggregation in cell assays and blocked clot formation in mice. These effects have not been measured in people taking oral rutin.
Clinical trials
Systematic review and meta-analysis of 15 randomized trials (1,643 participants) of hydroxyethylrutosides, semi-synthetic rutin derivatives sold as Relvène, Venoruton and Paroven, versus placebo or compression (Aziz et al. 2015, J Clin Pharm Ther)
Adults with chronic venous insufficiency.
Compared with placebo, hydroxyethylrutosides reduced leg pain, leg heaviness and cramps, and no serious adverse effects were reported. The authors called the improvements modest and judged all included trials to be of limited quality. This evidence is for the derivative, not for plain dietary rutin.
Randomized double-blind multicenter trial at four colorectal units: a five-flavonoid mixture (78 patients) versus a micronized diosmin-based flavonoid mixture (76 patients), with no placebo arm (Corsale et al. 2018, Int J Colorectal Dis)
154 patients with degree I to III hemorrhoidal disease.
Bleeding improved similarly in both groups at 1 month (79.5% vs 80.2%) and 6 months (70.5% vs 75%), with no significant difference. Satisfaction at 6 months was higher with the five-flavonoid mixture. Rutin was one of five ingredients and there was no placebo group, so the result cannot be attributed to plain rutin.
Double-blind randomized placebo-controlled trial of 500 mg/day rutin or placebo for 3 months (Bazyar et al. 2023, Phytother Res)
50 adults with type 2 diabetes (25 per group).
Compared with placebo, rutin lowered fasting glucose, insulin, HbA1c, insulin resistance, LDL and total cholesterol, the atherogenic index of plasma, IL-6 and malondialdehyde, and raised HDL and total antioxidant capacity. These were blood markers in one small trial, not clinical events.
Double-blind randomized placebo-controlled trial of 500 mg/day rutin as capsules or in yogurt for 12 weeks (Mathrani et al. 2023, Nutrients)
87 adults aged 18 to 65 with overweight and normal blood sugar or prediabetes.
Compliance was about 90%, but neither rutin capsules nor rutin yogurt changed pancreatic beta-cell response to an oral glucose tolerance test compared with placebo, and gut bacterial composition did not change significantly.
Randomized single-blind placebo-controlled trial of a 500 mg rutin supplement versus a glucose placebo for 6 weeks (Boyle et al. 2000, Eur J Clin Nutr)
18 healthy, non-obese women aged 18 to 48 with normal cholesterol.
Rutin raised blood levels of quercetin and related flavonoids but did not significantly change plasma antioxidant status or urinary oxidative stress markers. Blood chemistry and liver function tests showed no adverse changes. DNA oxidation in white blood cells fell in both groups, which the authors suggested may reflect seasonal diet changes.